For Immediate Release

Chicago, IL – October 16, 2009 – announces the latest Industry Outlook. Today, Zacks Equity Research discusses the Medical Devices sector, including Allscripts-Misys Healthcare Solutions, Inc. (MDRX), Omnicell Inc. (OMCL) and Merge Healthcare Incorporated (MRGE).

Here is the latest on the Medical Devices sector:

The global medical devices industry is fairly large and is valued at roughly $223 billion, with the U.S. accounting for approximately 41%. The industry is divided into different categories such as Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices and Healthcare IT.

In the medical devices space, we recommend that investors focus on companies providing life-sustaining products. These companies provide a strong recurring stream of revenues as patients are unable to forego these products. Furthermore, investors should allocate funds to companies with high-earnings-quality profiles.

Large companies with a wide portfolio of products are also better poised for good returns. These companies are capable of withstanding the current economic recession.

Another area which is interestingly poised for growth these days is Healthcare IT. The landscape has changed since the Obama Administration passed a health care stimulus package to encourage hospitals and physicians practices to modernize their health record keeping. Names in this area include Allscripts-Misys Healthcare Solutions, Inc. ( MDRX ), Omnicell Inc. (OMCL) and Merge Healthcare Incorporated (MRGE). However, none of these companies have the above-mentioned attributes that differentiate them from the others. As such, we have a Neutral rating on these stocks.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter:

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at

Visit for information about the performance numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Mark Vickery
Web Content Editor



Zacks Investment Research